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Abstract
Background: The combined treatment modality of ionizing radiation (IR) with inhibitors of angiogenesis (IoA) is a
promising treatment modality based on preclinical in vivo studies using heterotopic xeno- and allograft tumor
models. Nevertheless reservations still exist to translate this combined treatment modality into clinical trials, and
more advanced, spontaneous orthotopic tumor models are required for validation to study the efficacy and safety
of this treatment modality.
Findings: We therefore investigated the combined treatment modality of IR in combination with the clinically
relevant VEGF receptor (VEGFR) tyrosine kinase inhibitor PTK787 in the MMTV/c-neu induced mammary carcinoma
model and a syngenic allograft tumor model using athymic nude mice. Mice were treated with fractionated IR, the
VEGFR-inhibitor PTK787/ZK222584 (PTK787), or in combination, and efficacy and mechanistic-related endpoints
were probed in both tumor models. Overall the treatment response to the IoA was comparable in both tumor
models, demonstrating minimal tumor growth delay in response to PTK787 and PTK787-induced tumor hypoxia.
Interestingly spontaneously growing tumors were more radiosensitive than the allograft tumors. More important
combined treatment of irradiation with PTK787 resulted in a supraadditive tumor response in both tumor models
with a comparable enhancement factor, namely 1.5 and 1.4 in the allograft and in the spontaneous tumor model,
respectively.
Conclusions: These results demonstrate that IR in combination with VEGF-receptor tyrosine kinase inhibitors is a
valid, promising treatment modality, and that the treatment responses in spontaneous mammary carcinomas and
syngenic allografts tumor models are comparable.
Findings
Preclinical studies have demonstrated that the combined
treatment of IR with IoA is highly effective in xeno- and
allograft tumor models of breast cancer [1-3]. It is gen-
erally agreed that IR and IoA interact on the level of the
tumor microenvironment, although the exact mechan-
ism of synergistic action of these two treatment modal-
ities is still a matter of debate. For example, IoAs can
either improve tumor oxygenation by a mechanism
termed vascular normalization [4] and thereby sensitize
for IR, or IoAs can increase tumor hypoxia [3,5-7],
which is counteracted by combined treatment with IR.
The cause for these different treatment responses to
IoAs is unknown but might be related to differences in
the mode of action of the IoAs and the treatment regi-
mens including doses and scheduling, and the tumor
models used on the preclinical level [8]. With respect to
the tumor models used on the preclinical level, most
studies were performed with either orthotopic or het-
erotopic xenograft [4-6] or heterotopic allograft tumor
models [3]. Though, little is known about the relevance
of a differential microenvironment in xenograft versus
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regard to the treatment response to IoAs and in particu-
lar to a combined treatment modality of IoAs with IR
[9,10]
We previously demonstrated that the risk of enhanced
tumor hypoxia in response to the inhibitor of vascular
endothelial growth factor receptor 2 (VEGFR2) PTK787/
ZK222584 (PTK787) exists, but is minimal when
PTK787 is combined with IR [3]. Our experiments were
originally performed in a classic allograft tumor model
derived from NF9006 tumor cells, which were originally
established from spontaneous murine MMTV/c-neu dri-
ven mammary carcinomas. These fast-growing allografts
and their fast-developing tumor vasculature might not
represent the tumor microenvironment in a sponta-
neously growing tumor. We therefore revisited the
potential drawback of this artificial fast-growing tumor
model in the corresponding MMTV/(c-neu)-driven
spontaneously growing mammary tumor model and
compared the treatment-dependent responses with
those achieved in the syngenic allografts.
The female, heterozygous offspring of female FVB-
wild type mice, which were mated with male FVB-Tg
(MMTV/c-neu) mice (Charles River), developed mam-
mary carcinomas within 100 days after a first littering.
To generate the corresponding allograft tumor model,
mammary carcinoma cells (NF9006), which were estab-
lished from the spontaneous tumor model, were subcu-
taneously injected (4 × 10
6 cells) on the back of athymic
nude mice. Spontaneous tumors and allografts were
allowed to grow to 200 mm
3 ± 10% before start of treat-
ment. Mice carrying allograft tumors on their backs
were irradiated using a customized shielding device
whereas mice with spontaneous tumors in the mouse
breast were given upper-half-body radiotherapy. All
mice were treated with a minimally fractionated locore-
gional radiotherapy regimen of 4 × 3 Gy during 4 conse-
cutive days, using a Pantak Therapax 300-kV X-ray unit
at 0.7 Gy/min. PTK787 (dissolved in 5% DMSO, 1%
Tween-80 and 94% H2O) was applied orally either alone
(100 mg/kg) or 1 hour prior to irradiation. Immunohis-
tochemical stainings of tumor sections were performed
after tumor excision at day 4 of treatment. Detailed
descriptions of the experimental procedures are given
elsewhere [11]. The Student’s t-test was used to statisti-
c a l l ya n a l y s et h ed i f f e r e nces between the treatment
groups.
In comparison to the fast growing allograft tumor
model, which formed tumors in average within 14 days
after cell injection, orthotopic heterozygous FVB-Tg
(MMTV/c-neu) tumor formation required more than
100 days to reach the minimal treatment size of 200
mm
3. Thereafter tumor growth rates were comparable
between the two tumor models. Absolute tumor growth
delay (AGD) in response to treatment with the IoA
PTK787 alone was minimal in both tumor models
(Figure 1).
We previously observed a PTK787-induced increase of
tumor hypoxia using Glut-1 and pimonidazole staining
[3,11]. The hypoxia probe pimonidazole, which specifi-
cally accumulates in hypoxic tissue areas, was injected
45 min before mice killing. Two adjacent tumor sections
were then probed either with antibodies specific for the
endogenous hypoxia marker Glut-1 or for pimonidazole.
A speckled strongly-increased staining pattern with both
hypoxia markers was observed in response to PTK787-
treatment in both allografts and spontaneous tumors,
demonstrating a similar treatment response to this IoA
on the level of tumor hypoxia (Figure 2).
Interestingly, spontaneously growing tumors were
much more sensitive to treatment with IR alone, with
an AGD of 20.1 days to triple the initial treatment
volume in comparison to an AGD of 8.4 days for allo-
graft tumors (P < 0.001). Combined treatment with
PTK787 and IR resulted in a supra-additive treatment
response in both tumor models with an AGD of 14 and
30.4 days in the allograft and the spontaneous tumor
model, respectively (Figure 1, Table 1). More important
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Figure 1 Similar treatment response in spontaneous mammary
carcinoma and in a syngenic heterotopic allograft tumor
model. Tumor growth delay of syngenic mammary carcinoma
allografts (A) and orthotopic spontaneous mammary carcinomas (B)
in response to IR (4 × 3 Gy) and PTK787 (4 × 100 mg/kg) alone and
in combination. For the allograft tumor model 10-15 mice/group
and for the spontaneous tumor model 8-13 mice/group were used.
Each curve represents the mean tumor volume per group ± SE.
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Page 2 of 6the enhancement factor was comparable for the two
tumor models, namely 1.5 and 1.4 in the allograft and
in the spontaneous tumor model, respectively.
Tumor cell apoptosis and tumor cell proliferation
were investigated to analyze the effects of the two treat-
ment modalities (Figure 3). Tumor cell proliferation was
determined using immunohistochemistry for the Ki-67
protein, which is expressed during all phases of the cell
cycle, except G0. In both tumors models treatment with
PTK787 alone did not reduce the proliferative activity of
tumor cells whereas treatment with IR significantly
reduced tumor cell proliferation in comparison to con-
trol tumors (p < 0.001). Combined treatment with IR
and PTK787 did not further reduce the proliferative
Glut-1 Pimonidazole
Control
PTK787
Pimonidazole Glut-1
Allograft Tumor Model Spontaneous Tumor Model
1 mm 1 mm 1 mm 1 mm
1 mm 1 mm 1 mm 1 mm
Figure 2 Increased tumor hypoxia in response to PTK787-treatment. Immunohistochemical detection of tumor hypoxia with antibodies
against endogenous Glut-1 or the exogenous 2-nitroimidazole hypoxia marker pimonidazole hydrochloride in NF9006-derived allografts and
spontaneous mammary carcinomas. Mice with NF9006-derived allografts and spontaneous tumors were treated with PTK787 (100 mg/kg × 4).
Mice were sacrificed and tumors were harvested on day 4 of treatment.
Table 1 Results of Growth Delay Assays
Schedule Time in days for tumors to grow from 200 to 600 mm
3 Growth-AGD
†† Delay NGD
§ Endhancement Factor
ǁ
Allografts
Control 8.8 ± 0.9 -
PTK787 10.5 ± 0.5 1.7 - -
IR 17.2 ± 0.5 8.4 - -
PTK787+IR 22.8 ± 1.4 14.0 12.3 1.5
Spontanous Tumors
Control 11.5 ± 0.8 - - -
PTK787 14.3 ± 1.5 2.8 - -
IR 31.6 ± 2.8 20.1 -
PTK787+IR 41.9 ± 1.8 30.4 27.6 1.4
Effect of PTK787 on the radioresponse of allograft and spontaenous tumors measured by tumor growth delay. For treatment schedules see Figure 1.
††Absolute tumor growth delay (AGD) caused by PTK787, IR, or their combination is defined as the time in days required for tumor to triple tumor size from 200
to 600 mm
3 minus the time in days in untreated tumors.
§Normalized tumor growth delay (NGD) is defined as the time in days for tumors to triple tumor size in the mice treated with the combination of PTK787 and IR
minus the time in days to triple tumor size in mice treated with PTK787 alone.
ǁEnhancement factors obtained by dividing NGD in mice treated with PTK787 plus IR by the AGD in mice treated with IR alone.
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Page 3 of 6activity in both tumor models. Tumor cell apoptosis was
determined by terminal deoxynucleotidyl transferase-
mediated nick-end labeling (TUNEL). Treatment with
PTK787 did not induce tumor cell apoptosis in contrast
to treatment with IR alone, which resulted in an
approximately 3 fold increase of TUNEL-positive cells
in both tumor models (allograft: p < 0.001, spontaneous:
p < 0.01). Combined treatment with IR and PTK787
resulted in a similar absolute increase (appr. 5 fold) of
tumor cell apoptosis in comparison to control tumors (p
< 0.001). In comparison to the apoptotic treatment
response to IR alone, the amount of apoptotic tumor
cells in response to the combined treatment modality
was significantly further enhanced, but only for allo-
grafts (p < 0.001) and not for spontaneous tumors (p =
0.3), which showed a more heterogenous staining pat-
tern. Nevertheless, similar treatment-dependent effects
c o u l db ed e t e r m i n e di nt h ea l l o g r a f ta n ds p o n t a n e o u s
tumor models on the tumor cell level. To examine a
change in microvessel density in response to the
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Figure 3 Tumor cell proliferation, apoptosis, and microvessel density in response to PTK787 and IR. Mice with NF9006-derived allografts
or spontaneous mammary carcinomas were treated with PTK787 (100 mg/kg × 4), IR (4 Gy × 3), or in combination. At day 4 of treatment, mice
were sacrificed, and tumors were harvested, formalin fixed, and stained for the Ki-67 (A), TUNEL (B), and CD31 (C) as marker of tumor cell
proliferation, apoptosis, and microvessel density, respectively. Percentage CD31-positive cells and Ki-67- and TUNEL-positive nuclei per high-
powered fields (hpf) was determined in 4-10 randomly chosen visual fields in each of at least two similarly treated vital tumor tissues of
allografts and orthotopic tumors. For the allograft tumor tissue sections 3 mice/group and for the spontaneous tumor model tissue sections 2-4
mice/group were used. Each bar represents the mean value per group ± SD (*<0.05; **<0.01; ***<0.005).
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Page 4 of 6different treatment modalities, aCD31-stained tumor
vessels were counted in histological sections. The micro-
vessel density (MVD) was reduced on treatment with
PTK787 alone (p < 0.01) and was further decreased on
treatment with PTK787 and IR in combination (allograft
p < 0.001, spontaneous p < 0.05), again to a similar
extent in both tumor types (Figure 3). Thus, on the
level of the tumor microenvironment a significant com-
bined treatment effect could be observed on the level of
the tumor vasculature. Of note the spontaneous mam-
mary carcinoma tissue contained large lake-like cavities
or vessels but the MVD was similar to the allograft tis-
sue (see above Figure 2).
Here, we have examined the effects of the combined
treatment modality of ionizing radiation with the VEGF-
receptor tyrosine kinase inhibitor PTK787 in both a
spontaneous and a strongly related allograft mammary
carcinoma model. Little is known about differences in
the make-up of the tumor microenvironment between
allografts and xenografts, orthotopic and heterotopic
tumors. In the models used in this study, major differ-
ences with regard to the tumor biology, and eventually
to the treatment response, would rather be expected on
the level of the tumor microenvironment than on the
level of the syngenic tumor cells. Interestingly we
observed the strongest difference between the two
tumor models on the level of radiation sensitivity. The
NF9006 cell line, which is derived from a spontaneous
murine MMTV/c-neu driven mammary carcinoma, may
have acquainted additional mutations during the in vitro
establishment, and these genetic mutations might con-
tribute to the increased radiation resistant phenotype of
allografts derived from this cell line. On the other hand,
increased radiation sensitivity of spontaneous tumors in
comparison to allograft tumors may be linked to differ-
ences in the tumor vasculature as well as immunomodu-
latory effects in the immunocompetent host [12].
PTK787 exerts its antivascular effects by targeting the
VEGF receptor, which is almost exclusively located on
endothelial cells. The treatment responses to PTK787
alone were similar in both tumor models, which indicate
a similar phenotype and treatment sensitivity of the
respective endothelial cells. This is further supported by
a similar treatment-dependent reduction of microvessel
densities and a treatment-dependent increase of tumor
hypoxia.
We previously demonstrated that IoA induce tumor
hypoxia in allografts, which is counteracted by combined
treatment with irradiation [3]. Eventually combined
treatment results in a supraadditive treatment response.
Insofar our studies are of high clinical interest since
PTK787 exerted a similar treatment response in the
allograft and the spontaneously growing tumor model
with potent radiation enhancement to a similar extent
in both tumor models. Thereby the data strengthen the
evidence to overcome a major obstacle translating such
a treatment combination into the clinics, i.e. the suppo-
sition that a potential IoA-dependent increase of tumor
hypoxia might impair the treatment response to ionizing
radiation. Obtaining preclinical data with spontaneous
tumor models is highly laborious and cost-effective. Our
comparative study furthermore demonstrates that an
allograft tumor model is adequate and represents a valid
tumor model to investigate the combined treatment
modality of IR with IoA.
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